PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo

BACKGROUND: On-target off-tumor toxicity impedes the clinical application of chimeric antigen receptor-modified T cells (CAR-T cells) in the treatment of solid tumors. Previous reports proved that the combinatorial antigen recognition strategy could improve the safety profile of CAR-T cells by targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Qibin, Mao, Yunyu, He, Huan, Ding, Xiangqing, Zhang, Xiaoyan, Xu, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607631/
https://www.ncbi.nlm.nih.gov/pubmed/33292688
http://dx.doi.org/10.1186/s40364-020-00237-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607631/
https://www.ncbi.nlm.nih.gov/pubmed/33292688
http://dx.doi.org/10.1186/s40364-020-00237-w

Ejemplares similares